Suzhou Yikesai Biotechnology Co., Ltd
Suzhou Yikesai Biotechnology Co., Ltd., with the mission of "accelerating the application of life sciences and benefiting people's health", is committed to solving the bottleneck of biopharmaceuticals and achieving the localization of key raw materials. It has become one of the excellent enterprises in the upstream core raw materials of biopharmaceuticals in China. The company is a national high-tech enterprise, a national specialized and innovative small giant enterprise, a member of the China International Serum Industry Association (ISIA), and a research center for CD serum-free culture medium engineering in the fields of biopharmaceuticals and cell therapy in Jiangsu Province.
The company currently focuses on three major product segments: serum-free culture media, fetal bovine serum, and identification reagents, providing international quality products and services for customers in biopharmaceuticals, cell and gene therapy, and basic scientific research. The company relies on an international and specialized R&D technology team, quality and production team, and commercialization team to continuously innovate and pursue excellence. While continuously optimizing product performance, it ensures reliable quality and stable supply, fully empowering the rapid and healthy development of the biopharmaceutical industry, and creating cell culture "Chinese chip" products.
Recommended Posts
-
According to the World Health Organization, 90% of people worldwide breathe polluted air every day. Air pollution causes 7 million premature deaths annually due to diseases such as cancer, stroke, heart disease, and lung disease. 90% of premature deaths occur in low - to middle-income countries with high emissions of industrial, transportation, and agricultural pollutants. -
Cancer cells are very "cunning", they will use immune checkpoints to conceal their "bad person identity" - the proteins expressed on the surface of tumor cells will bind to the proteins on the surface of T cells, sending a signal to the immune system to "own people, don't kill me", thus avoiding the detection and attack of immune cells.Based on this principle, scientists have developed antibodies that block binding, namely immune checkpoint inhibitors, to achieve anti-cancer goals by releasing T cells. So far, the FDA has approved six immune checkpoint inhibitors targeting pathways, suitable for various cancers such as melanoma, non-small cell lung cancer, and renal cell carcinoma.
-
Big data, the Internet and artificial intelligence are promoting the digitization process of the medical system. The new intelligent and platform based applications will further enhance the quality of medical care and provide personalized solutions for disease prevention.Scientists, doctors, and engineers have invested considerable time in developing new digital applications. The goal of these tasks is not only to detect diseases in the early stages, but also to achieve disease prevention. Dr. Enise Lauterbach, a cardiologist from Trier, Germany, said, "The diagnosis and treatment of cardiovascular diseases are already very advanced in technology and have saved many lives. If diseases can be prevented, the effect will be even better
